Wealth Enhancement Advisory Services
PTCT icon

Wealth Enhancement Advisory Services’s PTC Therapeutics PTCT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
12,417
+1,290
+12% +$93.2K ﹤0.01% 2032
2026
Q1 		$754K Buy
11,127
+1,982
+22% +$140K ﹤0.01% 2003
2025
Q4 		$701K Buy
9,145
+806
+10% +$58.6K ﹤0.01% 2213
2025
Q3 		$533K Sell
8,339
-2,414
-22% -$126K ﹤0.01% 2319
2025
Q2 		$528K Sell
10,753
-917
-8% -$43.5K ﹤0.01% 2185
2025
Q1 		$595K Buy
+11,670
New +$582K ﹤0.01% 1921

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Wealth Enhancement Advisory Services's PTCT Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its PTC Therapeutics (PTCT) stake by 12% in Q2 2026, buying an estimated $93.2K and bringing the position to 12,417 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2032.

Wealth Enhancement Advisory Services first reported a position in PTCT in Q1 2025 and has held it in 6 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Wealth Enhancement Advisory Services held 12,417 shares of PTC Therapeutics worth $1.05M as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 1,290 PTC Therapeutics shares in Q2 2026, an estimated $93.2K.
  • PTC Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2032 holding.
  • Wealth Enhancement Advisory Services first reported a position in PTC Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.